Johnson & Johnson MedTech has announced a strategic co-promotion agreement with Pacira BioSciences, Inc. to enhance its Early Intervention portfolio for osteoarthritis of the knee. This collaboration introduces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), a non-opioid treatment option aimed at alleviating pain associated with osteoarthritis. The partnership aims to advance orthopaedic care by offering non-surgical solutions earlier in the treatment process, addressing the needs of over 30 million affected adults in the United States. The agreement also includes initiatives to increase professional education and patient engagement, focusing on providing effective, longer-lasting pain relief and improving patient outcomes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。